Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

Part of paid clinical trials in Newport Beach, California.

Sponsor
AstraZeneca
Study ID
NCT05303532
Phase
PHASE3
Status
Enrolling By Invitation

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Durvalumab — DRUG
    Fixed dose of 1500 mg via IV infusion upon enrollment visit and every 4 weeks thereafter.

Study Details

The rationale of the ROSY-D study is to continue to provide study treatment for patients who have participated in a parent study with Durvalumab and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.

Key Dates

Start date
Apr 19, 2022
Status verified
May 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
214 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Durvalumab
    Participants will receive durvalumab.

Primary Outcome Measure

Number of participants with serious adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [ Time Frame: From baseline up to follow up at 90 days after the last dose of study drug. ]

Locations (3)

FacilityCityStateZIPSite coordinators
Research SiteNewport BeachCalifornia92663-
Research SiteDenverColorado80218-
Research SiteMemphisTennessee38120-

Find similar trials in Newport Beach, CA

By research site
Research Site· Newport Beach, CAResearch Site· Denver, COResearch Site· Memphis, TN

Related Studies